Olea europaea in hypertension & metabolic syndrome

Size: px
Start display at page:

Download "Olea europaea in hypertension & metabolic syndrome"

Transcription

1 Olea europaea in hypertension & metabolic syndrome Cardio 017 The Hotel Michel P. HERMANS MD (UCL) PhD (UCL & Oxford, UK) Dip. Natural Sciences (Open University, Milton Keynes, UK) Dip. Earth Sciences (Open University, Milton Keynes, UK) Dip. Human Geography (Open University, Milton Keynes, UK) Dip. Environment (Open University, Milton Keynes, UK) PG Certificate in Social Sciences (Open University, Milton Keynes, UK) Endocrinologie & Nutri0on Cliniques universitaires St-Luc Université Catholique de Louvain

2 1. Hypertension & endothelial dysfunction 2. Tensiofytol : composition & MOA 3. Metabolic syndrome 4. Efficacy studies 5. PREDIMED study 6. Patient s profile & ongoing study

3 Physiopathology of Hypertension The blood pressure is the pressure of circulating blood on the walls of the arteries, it depends on the flexibility and the size of the arteries Constriction é Vascular Resistance When the diameter of the artery diminishes, the blood pressure increases Flexible blood vessel (dilatation & vasoconstriction) Rigid blood vessel (endothelial dysfunction) Endothelial dysfunction causes hypertension

4 Endothelium Endothelium Smooth Muscle cells The vascular endothelium is the inner layer (monocellular) of the blood vessels, the one in contact with the blood. Functions: Keeps the blood inside the blood vessels Regulation of the vascular permeability Molecular filter (exchange of nutrients) Regulation of the interaction between the vessel wall / leucocytes, platelets Regulation of the vasomotion: can liberate nitric oxide(no) which provokes vasodilatation The major cardiovascular pathologies like atherosclerosis, hypertension, diabetes are characterized by the dysfunction of the endothelial cells (often oxidative stress) with a reduction of the dependant relaxations of the endothelium.

5 1. Wolf-Maier et al Van Wijk et al Poorly-controlled Hypertension Badly controlled hypertension increases the risk of stroke, myocardial infarctions, auricular fibrillation, heart failure or kidney disease Control: Only 3 out of 10 patients with antihypertensive treatments 1 are monitored on the target values (<140/90 mmhg) > 2, the number of antihypertensive drugs needed to reach the target BP, in most of the clinical studies Low treatment compliance (bad adherence to treatment): Side effects/ cost of treatment / dosage 1 patient out of 2 stops the antihypertensive treatment after 3 years 2 Only 1 patient out of 5 resorting to specialized medical care for a resistant hypertension has been found to take all prescribed medicines during a test held in the Netherlands (Sympathy Study).

6 1. Hypertension & endothelial dysfunction 2. Tensiofytol : composition & MOA 3. Metabolic syndrome 4. Efficacy studies 5. PREDIMED study 6. Patient s profile & ongoing study

7 Daily dose 2 capsules: 334mg standardized olive leaf extract à 100mg oleuropein + EFSA: helps maintaining a normal blood pressure 106mg standardized olive extract à 20mg hydroxytyrosol EFSA: contributes to decreasing the oxidation of LDL cholesterol IMPROVES THE ENDOTHELIAL FUNCTION AND DECREASES THE BLOOD PRESSURE RECOMMENDED USE From 18 years : 2 capsules per day The first in the morning before breakfast and the second in the evening with a large glass of water

8 Active ingredients & metabolism Unique composition The best of 2 parts of the plant LEAF: Extract standardized in Oleuropein + FRUIT: Extract standardized in Hydroxytyrosol Oleuropein metabolizes à Hydroxytyrosol + other active metabolites Hydroxytyrosol immediately available through the fruit extract + Active substances in the extracts: phenolic derivatives, triterpenes (oleanolic acid) Fast and effective action, maximum concentrations after 2h for Oleuropein

9 Tensiofytol Mode of action Oleuropein & Hydroxytyrosol Rigid blood vessel (endothelial dysfunction) Flexible blood vessel (dilatation & vasoconstriction)

10 Treatment of Dyslipidemia Consumption of olive oil polyphenols contributes to the protection of LDL particles from oxidative damage The Panel concludes that a cause and effect relationship has been established between the consumption of olive oil polyphenols (standardized by their content of hydroxytyrosol and its derivatives) and protection of LDL particles from oxidative damage. The Panel considers that in order to bear the claim, 5 mg of hydroxytyrosol and its derivatives (e.g. oleuropein complex and tyrosol) should be consumed daily.

11 Tensiofytol Mode of action Focus on an endothelial cell : Oleuropein Hydroxytyrosol OXIDATIVE STRESS endothelial cell CAPTION: O2 : Superoxide NO : Nitric Oxide enos : Endothelial Nitric Oxide Synthase ONOO - : Peroxynitrite smooth muscle Oleuropein/Hydroxytyrosol : DOUBLE ACTION : diminishes the destruction of NO & increases the production of NO : IMPROVES THE ENDOTHELIAL FUNCTION AND THE FLEXIBILITY OF THE WALL Endothelial reactivity 2 Flexibility of blood vessels 2

12 1. Hypertension & endothelial dysfunction 2. Tensiofytol : composition & MOA 3. Metabolic syndrome 4. Efficacy studies 5. PREDIMED study 6. Patient s profile & ongoing study

13 Fatty tissue expansion Proinflammatory state muscle insulin resistance insulin signalling (PIP3 PKB/Akt) Atherogenic dyslipidemia adipocyte dysregulation IR-inducing secretory products and NEFAs; adiponectin apob-vldl-tg lipoproteins GLUT4 translocation glucose output hepatic insulin resistance glucose transport and uptake glycogen synthesis hepatic lipogenesis NAFL, NAFLD, NASH chronic hyperinsulinaemia IFG-IGT / T2DM in predisposed individuals

14 Selective IR & hyperinsulinemia hepatocyte HGO & hyperglycemia Steatosis and VLDL export vascular endotheliocyte Decreased NO Increased endothelin

15 muscle insulin resistance Nutritional-physical activity imbalance Proinflammatory state genetic &/or acquired mitochondrial defects (density/ function/biogenesis) oxidation capacity: sarcopenia, fiber type & distribution, ageing, obesity adipocyte dysregulation IR-inducing secretory products and NEFAs; adiponectin Atherogenic dyslipidemia apob-vldl-tg lipoproteins glucose output hepatic insulin resistance hepatic lipogenesis NAFL, NAFLD, NASH chronic hyperinsulinaemia IFG-IGT / T2DM in predisposed individuals

16

17 1. Hypertension & endothelial dysfunction 2. Tensiofytol : composition & MOA 3. Metabolic syndrome 4. Efficacy studies 5. PREDIMED study 6. Patient s profile & ongoing study

18 Efficiency + Mode of action Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension. Moreno-luna et al. Am. J. Hypertension, dec. 2012, Double blind cross-over on 24 women, 1 st diagnostic 11 women, prehypertension: SBP mmhg and/or DBP mmhg 13 women, mild hypertension: SBP mmhg and/or DBP mmhg Baseline after 4 months Mediterranean diet: Average Systolic Blood Pressure (SBP) 134,1 mmhg, average Diastolic Blood Pressure (DBP) 84.6 mmhg Treatment: virgin olive oil (VOO) vs. Placebo (olive oil without polyphenols) VOO: 60ml oil à 30 mg total polyphenols /day Duration: 2 months treatment 1 month wash out Switch 2 months treatment SBP= Systolic Blood Pressure DBP=Diastolic Blood Pressure Moreno-luna et al. Am. J. Hypertension, dec. 2012,

19 Efficiency + Mode of action Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension. Moreno-luna et al. Am. J. Hypertension, dec. 2012, Baseline after 4 months Mediterranean diet: Average Systolic Blood Pressure (SBP) 134,1 mmhg, average Diastolic Blood Pressure (DBP) 84.6 mmhg Results 1. Decrease SBP: -7,9 mmhg and DBP -6,7 mmhg, p< 0.01 vs. Baseline 2. Ox- LDL = - 28 μg/l p < CRP = mg/l p < Improvement of endothelial function; flexibility of the blood vessel wall. p < Increase in NO metabolites 60ml VOO(30mg Polyphenols): 134.1mmHg à 126.2mmHg 7.9mmHg p< 0.01

20 Efficiency Olive leaf extract Susalit 2011 Phytomedicine 18 (2011) Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: Comparison with Captopril Double blind study, olive leaf extract vs. Antihypertensive N=162 (148 evaluated), Patients with mild Hypertension (stage 1) SBP mmhg Baseline average SBP: ±5.58mmHg group olive leaf extract and ±5.56mmHg group Captopril; Baseline average DBP: 93.9 ±4.51and 93.8 ±4.88mmHg respectively Treatment: 500 mg leaf extract à 100 mg oleuropein (OE) 2x/d vs mg Captopril 2x/d. Captopril: the 1 st inhibitor of angiotensin-converting enzyme (ACE) Duration: 2 months

21 Efficiency Olive leaf extract Susalit 2011 Phytomedicine 18 (2011) Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: Comparison with Captopril Results: Decrease SBP/DBP= 11.5 / -4.8 mmhg with olive leaf extract -13.7/-6.4 mmhg with Captopril As efficient as Captopril (50mg/day) on the decrease of SBP and DBP Significant reduction of triglycerides: -23% (p<0.01) No effect on the triglycerides in the group of Captopril 1000mg OLE (200 OE): 149mmHg à mmhg 11.5mmHg

22 Efficiency Results Blood pressure 10mg Hydroxytyrosol 1x/day N=50 patients with metabolic syndrome Ischemic heart disease -35 % -50 % Lethal Cerebrovascular accident > Decrease of the cardiovascular risk LLewington S et al., Lancet. 2002;360: Meta-analysis on 61 observational studies (on 1 million adult patients) 7% Systolic Blood Pressure (mmhg) Diastolic Blood Pressure (mmhg) No statistical difference measured on the side effects between the treated group and placebo Decrease of 2 mmhg Coronary artery disease Systolic Blood pressure 10% Decrease of mortality due to a stroke

23 Efficiency Olive oil, in combination with antihypertensive drugs Perona 2004 Clinical Nutrition (2004) Virgin olive oil reduces blood pressure in hypertensive elderly subjects Randomized studies on elderly subjects with hypertension and treated since at least 5 years with beta blockers and diuretics N =62 : 31 Hypertensive + 31 Normotensive / 42 women 20 men Average age 84 years Treatment: 60g/day Virgin olive oil (VOO) vs. Sunflower oil Duration: 1 month treatment 1 month wash out Switch 1 month treatment

24 Efficiency Olive oil, in combination with antihypertensive drugs Perona 2004 Clinical Nutrition (2004) Virgin olive oil reduces blood pressure in hypertensive elderly subjects Results: Virgin olive oil (VOO), reduces the BP and normalizes the BP (136 mmhg) vs. Sunflower oil (150 ±8 mmhg). Virgin olive oil (VOO) reduced the total Cholesterol and the LDL-Cholesterol in the Normotensive patients (P<0:01) vs. Sunflower oil NT: Normotensive HT: Hypertensive SIGNIFICANT ACTION ON THE BLOOD PRESSURE IN ADDITION TO AN ANTIHYPERTENSIVE TREATMENT! VOO: 150 mmhg à 136 mmhg 14mmHg P<0.01 vs Sunflower oil VOO: Virgin Olive Oil SO: Sunflower oil

25 1. Hypertension & endothelial dysfunction 2. Tensiofytol : composition & MOA 3. Metabolic syndrome 4. Efficacy studies 5. PREDIMED & Mediterranean diet 6. Patient s profile & ongoing study

26 Prevention PREDIMED STUDY LONG-TERM EFFECT 7447 subjects during 4,8 years a. Mediterranean diet + Virgin olive oil: 1 liter/week b. Mediterranean diet + Nuts: 30g/ day (walnuts, hazelnuts, almonds) c. Control: low fat diet PREDIMED Study : 7447 subjects have followed one of these 3 diets during 4,8 years 9 Number of myocardial infarctions, strokes and deaths due to cardiovascular causes : Incidence of the cardiovascular events Control group Mediterranean diet + nuts Mediterranean diet + Extra Virgin olive oil -30% cardiovascular events (p<0,003) Years

27 Effect of a Traditional Mediterranean Diet on Lipoprotein Oxidation. JAMA Internal Medicine, individuals from the PREDIMED study who were at a high cardiovascular risk were assessed after 3 months The Mediterranean diet caused reductions in oxidized LDL cholesterol, along with improvements in several other heart disease risk factors VOO: Virgin Olive Oil

28 Olive oil Medina Remon 2015 Effects of total dietary polyphenols on plasma nitric oxide and blood pressure in a high cardiovascular risk cohort. The PREDIMED randomized trial 1 year intervention with two Mediterranean diets (Med-diet) could decrease blood pressure (BP) due to a high polyphenol consumption N= 200 high CV risk (elderly) 1 year EVOO vs. Med-nuts / randomized controlled clinical trial Measure: BP, NO, Total Polyphenol Excretion (TPE) Systolic and diastolic BP decreased significantly after a one-year dietary intervention with Med-EVOO and Med-nuts. These changes were associated with a significant increase in TPE and plasma NO. Additionally, a significant positive correlation was observed between changes in urinary TPE, a biomarker of TP intake, and in plasma NO.

29 Hydroxytyrosol Reduction in Incidence of T2DM with Mediterranean Diet Results of the PREDIMED-Reus nutrition intervention randomized trial This was a three-arm randomized trial in 418 non-diabetic subjects aged years recruited in one center Participants were randomly assigned to education on a low-fat diet (control group) or to one of two MedDiets, supplemented with either free virgin olive oil (1 liter/week) or nuts (30 g/day), for 4 years diabetes incidence reduced by 52% A = olive oil C = control P<0.047

30 Mode of action Meta-analyse Olive oil Schwingshackl 2015 nutrients Effects of Olive Oil on Markers of Inflammation and Endothelial Function A Systematic Review and Meta-Analysis Action olive oil : Inflammation Marker and Endothelial Function 30 studies / 3106 patients Dosage: 1 50 mg /day ê significant CRP (C-Reactive Protein)(p<0.0001) n=15 studies ê significant IL-6 (Interleukin-6) (p<0.04 Improvement of the endothelial function (NO)/ (p<0.002) n=8 é flow-mediated dilation(fmd ) Olive oil exerts beneficial effects on the endothelial functions and on the inflammation markers à contributes to the cardiovascular protection linked to the Mediterranean diet

31 Mode of action Meta-analyse Olive oil Schwingshackl 2015 nutrients Effects of Olive Oil on Markers of Inflammation and Endothelial Function A Systematic Review and Meta-Analysis Improvement of the endothelial function (NO)/ n=8 studies 335 patients é flow-mediated dilation (FMD) p<0.002

32 1. Hypertension & endothelial dysfunction 2. Tensiofytol : composition & MOA 3. Metabolic syndrome 4. Efficacy studies 5. PREDIMED study 6. Patient s profile & ongoing study

33 To whom advice early natural medical care? Measure the BP (mmhg) Optimal BP Pre-hypertension Normal HT HT stage 1 Tensiofytol vs. Antihypertensive drugs + Action on the other risk factors: Triglycerides, oxldl, HDL, glycemia (glucose intolerance) Symptomatic Asymptomatic Symptomatic Prevention advice Lifestyle Medical evaluation Study of associated CVRF + evaluation of complications + Etiology Control 1/year Control every 6 months Check regularly Study of associated CVRF + evaluation of complications Pharmacological treatment Profiles of patients at risk? > 45 years > 50 years Regular BP > 130/80 mmhg In pre- or post-menopause n Family history of hypertension n high cholesterol level n Overweight n Sedentary n Keen on salt - prepared dishes n Metabolic syndrome Dietary supplement targeted standardized at : n 100 mg oleuropein n 20 mg hydroxytyrosol Dietary supplement targeted* standardized at : n 100 mg oleuropein n 20 mg hydroxytyrosol *If the targeted blood pressure remains difficult to reach with the pharmacologocal treatment and lifestyle

34 Morten and Vidiendal Olsen Evaluation of endothelial function by peripheral arterial tonometry and relation with the nitric oxide pathway. Nitric Oxide 2014 Reactive Ischemia Hyperemia (RIH) EndoPat 2000, Itamar

35 EndoPat 2000 system 6 minutes rest 5 minutes of ischemia Left arm 6 minutes post ischemia Right arm

36 On going study at ULG/Cardio service : vasodilating effect of Tensiofytol evaluated with the EndoPat T0 T 1 hour 2 caps (100 mg oleuropéine 20 mg hydroxytyrosol)

37

Managing High Blood Pressure Naturally. Michael A. Smith, MD Life Extension s Healthy Talk Series

Managing High Blood Pressure Naturally. Michael A. Smith, MD Life Extension s Healthy Talk Series Managing High Blood Pressure Naturally Michael A. Smith, MD Life Extension s Healthy Talk Series Part 1 What is Blood Pressure? Blood Pressure Systole Systolic Forward Pressure 110 mmhg 70 mmhg Diastole

More information

Traditional Asian Soyfoods. Proven and Proposed Cardiovascular Benefits of Soyfoods. Reduction (%) in CHD Mortality in Eastern Finland ( )

Traditional Asian Soyfoods. Proven and Proposed Cardiovascular Benefits of Soyfoods. Reduction (%) in CHD Mortality in Eastern Finland ( ) Proven and Proposed Cardiovascular Benefits of Soyfoods Mark Messina, PhD, MS Soy Nutrition Institute Loma Linda University Nutrition Matters, Inc. markjohnmessina@gmail.com 1000 80 20 60 40 40 60 20 80

More information

THE SAME EFFECT WAS NOT FOUND WITH SPIRITS 3-5 DRINKS OF SPIRITS PER DAY WAS ASSOCIATED WITH INCREASED MORTALITY

THE SAME EFFECT WAS NOT FOUND WITH SPIRITS 3-5 DRINKS OF SPIRITS PER DAY WAS ASSOCIATED WITH INCREASED MORTALITY ALCOHOL NEGATIVE CORRELATION BETWEEN 1-2 DRINKS PER DAY AND THE INCIDENCE OF CARDIOVASCULAR DISEASE SOME HAVE SHOWN THAT EVEN 3-4 DRINKS PER DAY CAN BE BENEFICIAL - WHILE OTHERS HAVE FOUND IT TO BE HARMFUL

More information

http://noodlemaz.wordpress.com/category/science/cancer/ Outline Introduction Serious nature of Cardiovascular Disease (CVD) How to prevent CVD? The disease process Damage and plaque development Current

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

Proven and Proposed Cardiovascular Benefits of Soyfoods

Proven and Proposed Cardiovascular Benefits of Soyfoods Proven and Proposed Cardiovascular Benefits of Soyfoods Mark Messina, PhD, MS Soy Nutrition Institute Loma Linda University Nutrition Matters, Inc. markjohnmessina@gmail.com Alpro Foundation 20 years symposium

More information

NATURAL INGREDIENTS TO SUPPORT HEART HEALTH a focus on Mediterranean botanical extracts

NATURAL INGREDIENTS TO SUPPORT HEART HEALTH a focus on Mediterranean botanical extracts NATURAL INGREDIENTS TO SUPPORT HEART HEALTH a focus on Mediterranean botanical extracts Yannick Capelle Product Manager Frutarom Health Cardiovascular Health Risk factors Health conditions with high prevalence

More information

INC International Nut & Dried Fruit Council Symposium Nuts in Health and Disease. Granada, 19 th September 2013 Press Kit

INC International Nut & Dried Fruit Council Symposium Nuts in Health and Disease. Granada, 19 th September 2013 Press Kit INC International Nut & Dried Fruit Council Symposium Nuts in Health and Disease Granada, 19 th September 2013 Press Kit Index Introduction Keynote Speakers Conference Abstract Useful Information The International

More information

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Content Introduction The number 1 killer in America Some statistics

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of

More information

The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease

The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D

More information

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

More information

Maintain Cholesterol

Maintain Cholesterol Maintain Cholesterol What is Cholesterol? Cholesterol is a Lipid Molecule that has a waxy appearance and is found in every cell of the body and has some important natural functions. It is manufactured

More information

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1

More information

Can red yeast rice & olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind randomized controlled trial

Can red yeast rice & olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind randomized controlled trial Can red yeast rice & olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind randomized controlled trial Prof. Dr. N. Hermans Department of Pharmaceutical Sciences,

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

Heart Disease Genesis

Heart Disease Genesis Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME What does the term Metabolic Syndrome describe? Metabolic syndrome describes a cluster of cardio-metabolic conditions that increase one's risk of developing

More information

Dysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale

Dysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±

More information

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced

More information

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids: CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation

More information

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for

More information

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial

More information

Cardiovascular Disease Risk Factors:

Cardiovascular Disease Risk Factors: Cardiovascular Disease Risk Factors: Risk factors are traits or habits that increase a person's chances of having cardiovascular disease. Some risk factors can be changed. These risk factors are high blood

More information

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H. U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?

Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010 Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010 Content Introduction The number 1 killer in America Some statistics

More information

Cardiac Pathophysiology

Cardiac Pathophysiology Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of

More information

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Heart Attack. PART 2. Health Issues of Special Interest to Women. Heart and Artery Diseases. Chapter 4

Heart Attack. PART 2. Health Issues of Special Interest to Women. Heart and Artery Diseases. Chapter 4 PART 2. Health Issues of Special Interest to Women Heart Attack Heart and Artery Diseases Chapter 4 You may not know that diseases of the heart and arteries (primarily heart attack, heart disease, high

More information

Chapter 18. Diet and Health

Chapter 18. Diet and Health Chapter 18 Diet and Health Risk Factors and Chronic Diseases Interrelationships among Chronic Diseases Chronic Disease Heart Disease and Stroke Hypertension Cancer Diabetes The Formation of Plaques in

More information

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016 Juniata College Screening Results Juniata College Screening Results October 11, 2016 & October 12, 2016 JUNIATA COLLEGE The J.C. Blair Hospital CARES team screened 55 Juniata College employees on October

More information

Essential Fatty Acids Essential for Good Health SIE

Essential Fatty Acids Essential for Good Health SIE Page 1 of 6 Essential Fatty Acids Essential for Good Health SIE By Yousry Naguib, PhD Essential fatty acids (EFAs) must be obtained through the diet and cannot be synthesized by the human body. EFAs are

More information

METABOLISM of ADIPOSE TISSUE

METABOLISM of ADIPOSE TISSUE METABOLISM of ADIPOSE TISSUE 2. LF UK Prof. Rudolf Poledne, PhD. TYPES OF ADIPOSE TISSUE brown adipose tissue subcutaneous adipose tissue visceral adipose tissue ADIPOSE TISSUE FUNCTIONS: thermal isolation

More information

Session 21: Heart Health

Session 21: Heart Health Session 21: Heart Health Heart disease and stroke are the leading causes of death in the world for both men and women. People with pre-diabetes, diabetes, and/or the metabolic syndrome are at higher risk

More information

Metabolic Syndrome. DOPE amines COGS 163

Metabolic Syndrome. DOPE amines COGS 163 Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

Five chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple

More information

ASSeSSing the risk of fatal cardiovascular disease

ASSeSSing the risk of fatal cardiovascular disease ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril

More information

Summary of recommendations

Summary of recommendations Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:

More information

Cardiovascular Diseases and Diabetes

Cardiovascular Diseases and Diabetes Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular

More information

American Diabetes Association: Standards of Medical Care in Diabetes 2015

American Diabetes Association: Standards of Medical Care in Diabetes 2015 American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform

More information

Mechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment

Mechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment Mechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment Mandeep Sidhu, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Albany Medical College

More information

A Review of Health Benefits of Cherries

A Review of Health Benefits of Cherries A Review of Health Benefits of Cherries Darshan S. Kelley PhD Western Human Nutrition Research Center, ARS, USDA and Department of Nutrition, University of California, Davis March 22, 2018, Suncadia Resort,

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Dyslipidemia Endothelial dysfunction Free radicals Immunologic ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and

More information

Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh

Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh "Insight Heart" is also available at www.squarepharma.com.bd Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh Coronary heart disease has been emerging as an

More information

Improving Access to Quality Medical Care Webinar Series

Improving Access to Quality Medical Care Webinar Series Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX

More information

Risk Factors for Heart Disease

Risk Factors for Heart Disease Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress

More information

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants Aggregate Report Fasting Biometric Screening CLIENTXXXX May 2, 2014 21,000 participants Contact:404.636.9437~Website:www.atlantahealthsys.com RISK FACTOR QUESTIONNAIRE Participants Percent Do not exercise

More information

OUR MISSION: DELIVERING THE PROOF OF THE

OUR MISSION: DELIVERING THE PROOF OF THE OUR MISSION: DELIVERING THE PROOF OF THE HEALTH EFFECTS REVIEW OF THE LATEST RESEARCH INTO DIETARY RISKS TO CARDIO HEALTH AND THEIR IMPLICATIONS FOR FOOD DEVELOPMENT ERIC CHAPPUIS DIRECTOR, CONSULTING

More information

WHICH DIET FOR THE PREVENTION OF CARDIOVASCULAR DISEASE MEAT OR VEGETARISM

WHICH DIET FOR THE PREVENTION OF CARDIOVASCULAR DISEASE MEAT OR VEGETARISM WHICH DIET FOR THE PREVENTION OF CARDIOVASCULAR DISEASE MEAT OR VEGETARISM QUELLE ALIMENTATION POUR PRÉVENIR LES MALADIES CARDIOVASCULAIRES VIANDE OU VÉGÉTARISME Dr Jean-Michel LECERF Service de Nutrition

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

STUDY OVERVIEW KEY TAKEAWAYS

STUDY OVERVIEW KEY TAKEAWAYS Avocado fruit on postprandial markers of cardio-metabolic risk: A randomized controlled dose response trial in overweight and obese men and women Britt Burton-Freeman, Eunyoung Park, Indika Edirisinghe

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Clinical Care Performance. Financial Year 2012 to 2018

Clinical Care Performance. Financial Year 2012 to 2018 Clinical Care Performance Financial Year 2012 to 2018 SHP Clinical Care Performance Diabetes Mellitus Hyperlipidemia Hypertension Diabetes Mellitus Find out how our patients are doing for: HbA1C HbA1c

More information

Establishment of Efficacy of Intervention in those with Metabolic Syndrome. Dr Wendy Russell - ILSI Europe Expert Group

Establishment of Efficacy of Intervention in those with Metabolic Syndrome. Dr Wendy Russell - ILSI Europe Expert Group Establishment of Efficacy of Intervention in those with Metabolic Syndrome Dr Wendy Russell - ILSI Europe Expert Group Conflict of interest regarding this presentation: I have no conflict of interest to

More information

β adrenergic blockade, a renal perspective Prof S O McLigeyo

β adrenergic blockade, a renal perspective Prof S O McLigeyo β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant

More information

Cardiovascular System and Health. Chapter 15

Cardiovascular System and Health. Chapter 15 Cardiovascular System and Health Chapter 15 Cardiovascular Disease Leading cause of death in U.S. Claims 1 life every 43 seconds Often, the first sign is a fatal heart attack Death Rates #1 CVD #2 Cancer

More information

Cho et al., 2009 Journal of Cardiology (2009), 54:

Cho et al., 2009 Journal of Cardiology (2009), 54: Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015 Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

More information

Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions

Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

A real life example In human studies, we quantify ~120 plasma related proteins Monocytes MMP9 Macrophages TNFα IL1ß platelet derived growth factor IFNγ MMP1 MMP8 MMP13 Myeloid Related Protein14 CD40

More information

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes

More information

Creating Healthier Lives. Cholesterol Reduction Complex Lower Your Cholesterol Naturally

Creating Healthier Lives. Cholesterol Reduction Complex Lower Your Cholesterol Naturally Cholesterol Reduction Complex Lower Your Cholesterol Naturally 1 DID YOU KNOW? About 40% of Canadian adults have high cholesterol. 2 DID YOU KNOW? YOU ARE AT RISK FOR HIGH CHOLESTEROL If you have a poor

More information

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic

More information

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??

More information

Diet, nutrition and cardio vascular diseases. By Dr. Mona Mortada

Diet, nutrition and cardio vascular diseases. By Dr. Mona Mortada Diet, nutrition and cardio vascular diseases By Dr. Mona Mortada Contents Introduction Diet, Diet, physical activity and cardiovascular disease Fatty Fatty acids and dietary cholesterol Dietary Dietary

More information

Mediterranean Diet: Choose this heart-healthy diet option

Mediterranean Diet: Choose this heart-healthy diet option Mediterranean Diet: Choose this heart-healthy diet option The Mediterranean diet is a heart-healthy eating plan combining elements of Mediterraneanstyle cooking. Here s how to adopt the Mediterranean diet.

More information

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Association between arterial stiffness and cardiovascular risk factors in a pediatric population + Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro

More information

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

Know Your Numbers Blood Pressure Cholesterol Blood Sugar

Know Your Numbers Blood Pressure Cholesterol Blood Sugar Know Your Numbers Blood Pressure Cholesterol Blood Sugar 2015 Wellness Warriors Sponsored by: Wayne State University Presented by: Debbie Cavender, RDN STRATEGIC WELLNESS, LLC The information in this presentation

More information

Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.

Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes Stephen D. Sisson MD Objectives To review dietary recommendations in the following conditions: Obesity Hypertension Diabetes

More information

Arteriosclerosis & Atherosclerosis

Arteriosclerosis & Atherosclerosis Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,

More information

Diabetic Dyslipidemia

Diabetic Dyslipidemia Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals

More information

Glossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein

More information

Put your Heart before your Head

Put your Heart before your Head Put your Heart before your Head Alok K Gupta, MD, FAAFP, FASH Associate Professor, Outpatient Clinic since 1963, the US Congress has required the President to proclaim February "American Heart Month."

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

PHENOTYPING FAMILIES OF A HYPERTENSIVE PATIENT

PHENOTYPING FAMILIES OF A HYPERTENSIVE PATIENT PHENOTYPING FAMILIES OF A HYPERTENSIVE PATIENT Christian Delles BHF Glasgow Cardiovascular Research Centre Advantages Cardiovascular of a Family-based ContinuumDesign Related subjects are more likely to

More information

How Low Do We Go? Update on Hypertension

How Low Do We Go? Update on Hypertension How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states

More information